MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Nicotine"

  • 2026 International Congress

    Clinical Impact of Nicotine in Parkinson’s Disease: Evidence from Randomized Controlled Studies

    J. Pitton Rissardo, J. Patino, A. Fornari Caprara, A. Mcgarry, I. Walker (Camden, USA)

    Objective: To evaluate the effects of nicotine versus placebo in Parkinson’s disease (PD). Background: Nicotine may influence dopaminergic and non‑dopaminergic pathways relevant to PD. While…
  • 2026 International Congress

    Pesticide Exposure and Smoking in Parkinson’s Disease in Kyrgyzstan: A Case–Control Study

    A. Kubanychbekova, A. Ismailova, E. Zhunusova, S. Kyialbekova, A. Abdumalikova, C. Shambetova (Bishkek, Kyrgyzstan)

    Objective: To investigate environmental exposures associated with Parkinson’s disease (PD) in Kyrgyzstan, focusing on pesticide exposure and smoking, and to explore potential sex-stratified associations. Background:…
  • 2025 International Congress

    Efficacy and Safety of Nicotine in Parkinson’s Disease: A Systematic Review and Meta-analysis

    O. Razouk, A. Ahmad, K. Mustafa, A. Habib, A. Al Midani (Sharjah, United Arab Emirates)

    Objective: This systematic review and meta-analysis aimed to evaluate the safety and efficacy of nicotine compared with placebo in the treatment of Parkinson’s disease (PD).…
  • 2024 International Congress

    The role of pathology validation on the association between smoking and Parkinson’s Disease

    P. Pecoraro, S. Carbone, F. Alessi, V. Di Lazzaro, L. Di Biase (Rome, Italy)

    Objective: The aim of this study is to investigate the relationship between smoking and Parkinson’s disease in pathology validated Parkinson’s disease patients. Background: Literature has…
  • 2022 International Congress

    Nicotine and influences on hyperkinetic movement disorders

    J. Qiu, L. Williams, H. Morales-Briceño, D. Olszewska, T. Lynch, V. Fung (Sydney, Australia)

    Objective: We describe hyperkinetic movement disorders with a variable response to smoking and nicotine and review clinical and pre-clinical evidence regarding the role of smoking,…
  • MDS Virtual Congress 2021

    Is the association between cigarette smoking and Parkinson disease causal? A Mendelian Randomization study.

    C. Domenighetti, PE. Sugier, A. Ashokkumar Sreelatha, C. Schulte, S. Grover, O. Mohamed, B. Portugal, P. May, D. Bobbili, M. Radivojkov-Blagojevic, P. Lichtner, R. Krüger, T. Gasser, M. Sharma, A. Elbaz (Villejuif Cedex, France)

    Objective: To determine whether the association between cigarette smoking and Parkinson disease (PD) is causal using 2-sample Mendelian randomization (MR) and to examine the potential…
  • MDS Virtual Congress 2021

    Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease

    C. Gabbert, I. König, T. Lüth, M. Kasten, A. Grünewald, C. Klein, J. Trinh (Lübeck, Germany)

    Objective: To investigate a possible association between smoking, the consumption of caffeine and the use of aspirin on age at onset (AAO), motor and non-motor…
  • MDS Virtual Congress 2021

    Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson’s disease

    YJ. Jung, H. Choi, E. Oh (Seoul, Republic of Korea)

    Objective: The objective of this study was to determine the potential neurotoxicity of fine particulate matter (FPM) and the neuroprotective properties of nicotine in the pathogenesis…
  • 2019 International Congress

    Preoperative Smoking History Increases Risk of Infection in Deep Brain Stimulation Surgery

    M. Sikora, F. Farrokhi, M. Marsans, S. Monsell, A. Wright, M. Palmer, A. Hoefer, P. Mcleod, J. Mark, J. Carlson (Seattle, WA, USA)

    Objective: Although general risk of deep brain stimulation (DBS) therapy has been previously described, application of risk prediction at the individual patient level is still…
  • 2018 International Congress

    The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America

    W. Oertel, H. Müller, C. Schade-Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, M. Unger, K. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

    Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…
  • 1
  • 2
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley